Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mystery Shopper Arana Stops Trading On ASX Until “Take Over” Announced

This article was originally published in PharmAsia News

Executive Summary

PERTH, Australia - Aussie biotech Arana announced Feb. 26 that it has engaged in take-over discussions and halted trading on the Australian Stock Exchange in anticipation of the take over

You may also be interested in...



Cephalon Launches Takeover Bid For Australian Biotech Arana

Arana’s lead compound ART621 is a new-generation TNF alpha blocker in Phase II trials for rheumatoid arthritis and psoriasis.

Cephalon Launches Takeover Bid For Australian Biotech Arana

PERTH, Australia - Sydney-based biotech Arana Therapeutics announced Feb. 27 that Cephalon intends to make a cash takeover offer for all of Arana's shares at a price of $1.40 per share

Cephalon Launches Takeover Bid For Australian Biotech Arana

Arana’s lead compound ART621 is a new-generation TNF alpha blocker in Phase II trials for rheumatoid arthritis and psoriasis.

UsernamePublicRestriction

Register

LL1134361

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel